// App-Quantinova.ai

140 : Continued Treatment with Nintedanib in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs): Data from INBUILD-ON

Researchers

Presenter

  • Eric Matteson

Principal Investigators

  • Danielle Antin-Ozerkis

  • Francesco Bonella

  • Nazia Chaudhuri

  • Vincent Cottin

  • Heiko Müller

  • Carl Coeck

  • Klaus Rohr

  • Wim Wuyts

Medical Centers

  • Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester

  • Section of Pulmonary, Critical Care and Sleep Medicine, Yale University School of Medicine, New Haven, CT

  • Center for interstitial and rare lung disease, Pneumology Department, Ruhrlandklinik University Hospital Essen, University Duisburg-Essen, Essen, Germany

  • North West Interstitial Lung Disease Unit, Manchester University Foundation Trust, Wythenshawe, Manchester, United Kingdom

  • Coordinating Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, University of Lyon, INRAE, Lyon, France

  • Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, Biberach, Germany

  • Boehringer Ingelheim SComm, Brussels, Brussels, Belgium

  • Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany,

  • Unit for Interstitial Lung Diseases, Department of Respiratory Medicine, University Hospitals Leuven, Leuven, Belgium,

Locations

  • United States

  • Germany

  • United Kingdom

  • France

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Nintedanib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved